

# Depression and anxiety in patients with rheumatoid arthritis

Mahdi Naeim

Department Psychology, Mohaghegh Ardabili University, Ardabil, Iran

The purpose of this correspondence is to highlight the importance of addressing mental health issues in RA patients and to suggest potential avenues for further research and clinical practice. Depression and anxiety are common comorbidities in people with rheumatoid arthritis that affect overall health and disease outcomes. Several studies have reported a high prevalence of depression and anxiety among RA patients, although the exact figures vary from study to study. Understanding the underlying mechanisms contributing to this association and its implications for patient care is essential [1,2].

One possible explanation for the high rates of depression and anxiety in RA is the shared etiological factors between these conditions. Both RA and mental health disorders are associated with immune dysregulation and inflammation. Chronic inflammation, a hallmark of RA, can affect neurotransmitter function and contribute to mood disorders. In addition, psychological factors such as stress and maladaptive coping mechanisms may exacerbate both RA symptoms and mental health problems [3,4].

The impact of depression and anxiety on disease outcomes in RA should not be underestimated. Several studies have shown a bidirectional relationship between mental health and RA outcomes. Depression and anxiety can worsen disease activity, functional impairment, and treatment response. Conversely, RA-related factors such as pain and disability can contribute to the development and course of depression and anxiety. Therefore, a comprehensive approach to RA management should include assessment and management of mental health issues [5,6].

Screening for depression and anxiety in RA patients is very important for early diagnosis and intervention. Various screening tools have been validated for use in clinical practice, such as the Patient Health Questionnaire-9 (PHQ-9) for depression and the 7-item Generalized Anxiety Disorder Scale (GAD-7) for anxiety. Integrating mental health screening into routine rheumatology care can help identify patients who may benefit from further evaluation and treatment [2,7].

Treatment of depression and anxiety in RA should include a multidisciplinary approach. Drug therapy, psychotherapy, and lifestyle interventions have all shown effectiveness in managing these conditions. Collaborative care models involving rheumatologists, mental health professionals, and other health care providers can optimize patient outcomes and improve their overall quality of life [4,8].

Moving forward, several areas warrant further research. Longitudinal studies are needed to clarify the temporal relationship between mental health and RA, as well as the impact of mental health interventions on disease outcomes. In addition, research focusing on the development of targeted interventions, specifically designed for RA patients with depression and anxiety, would be beneficial.

As a result, depression and anxiety significantly affect the lives of patients with rheumatoid arthritis. Recognizing and addressing these mental health issues is an essential component of comprehensive care for people with RA. By integrating mental health screening and management into routine rheumatology practice, we can improve patient outcomes and increase their overall well-being.

## REFERENCES

1. Itaya T, Torii M, Hashimoto M, Tanigawa K, Urai Y, Kinoshita A, et al. Prevalence of anxiety and depression in patients with rheumatoid arthritis before and during the COVID-19 pandemic. *Rheumatology*. 2021 Apr 1;60(4):2023-4. doi: 10.1093/rheumatology/keab065.
2. Isik A, Koca SS, Ozturk A, Mermi O. Anxiety and depression in patients with rheumatoid arthritis. *Clin Rheumatol*. 2007 Jun;26:872-8. doi: 10.1007/s10067-006-0407-y.
3. Matcham F, Ali S, Irving K, Hotopf M, Chalder T. Are depression and anxiety associated with disease activity in rheumatoid arthritis? A prospective study. *BMC Musculoskelet Disord*. 2016 Dec;17(1):1-9. doi: 10.1186/s12891-016-1011-1.
4. Katchamart W, Narongroeknawin P, Chanapai W, Thaweeratthakul P, Srisomnuek A. Prevalence of and factors associated with depression and anxiety in patients with rheumatoid arthritis: a multicenter prospective cross-sectional study. *Int J Rheum Dis*. 2020 Mar;23(3):302-8. doi: 10.1111/1756-185X.13781.
5. Fragoulis GE, Cavanagh J, Tindell A, Derakhshan M, Paterson C, Porter D, et al. Depression and anxiety in an early rheumatoid arthritis inception cohort. associations with demographic, socioeconomic and disease features. *RMD Open*. 2020 Oct 1;6(3):e001376. doi: 10.1136/rmdopen-2020-001376.
6. Hitchon CA, Zhang L, Peschken CA, Lix LM, Graff LA, Fisk JD, et al. Validity and reliability of screening measures for depression and anxiety disorders in rheumatoid arthritis. *Arthritis Care Res*. 2020 Aug;72(8):1130-9. doi: 10.1002/acr.24011.
7. Tiosano S, Yavne Y, Watad A, Langevitz P, Lidar M, Feld J, et al. The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis. *Eu J Clin Invest*. 2020 Sep;50(9):e13268. doi: 10.1111/eci.13268.
8. Manning-Bennett AT, Hopkins AM, Sorich MJ, Proudman SM, Foster DJR, Abuhelwa AY, Wiese MD. The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis - a pooled analysis of five randomised controlled trials. *Ther Adv Musculoskelet Dis*. 2022 Jul 22;14:1759720X221111613. doi: 10.1177/1759720X221111613.